Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 5, 2026Liver International

TNF‐α Inhibitors and HBV Reactivation Risk in HBsAg−/Anti‐HBc+ Patients: A Systematic Review and Meta‐Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMeng Hsuan KuoPKPing‐Hung KoCLChen‐Chou Lee

Discussion

Loading...

Member takes

Overview

Systematic review assesses TNF‐α inhibitor potency and HBV reactivation risk in HBsAg−/anti‐HBc+ individuals, suggesting ongoing monitoring is essential.

Key Points

  • This research aims to determine if the potency of TNF‐α inhibitors affects the risk of HBV reactivation in HBsAg−/anti‐HBc+ patients.
  • Conducted systematic review and meta-analysis of cohort studies and randomized trials.
  • Searched databases including PubMed and Embase for relevant studies.
  • Assessed risk of bias using the Newcastle-Ottawa Scale and RoB 2.0 methodology.
  • Calculated pooled HBV incidence and risk ratios using random-effects meta-analysis.
  • Identified 13 cohorts with a total of 1492 patients and 37 HBV reactivation events.
  • Pooled incidence of HBV reactivation was low at 2.3%.
  • High-potency TNF‐α inhibitors had a 3.9% incidence, while low-potency had 3.6%.
  • Anti-HBs seronegativity was linked to a higher risk of reactivation at 8.2%.

Cite This Study

Kuo et al. (2026) studied this question.

synapsesocial.com/papers/6984348bf1d9ada3c1fb2bf2https://doi.org/10.1111/liv.70532
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1RoB 2: a revised tool for assessing risk of bias in randomised trials2019 · 33,351 citations
  2. 2Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences2017 · 15 citations
  3. 3Moderate Risk of Hepatitis B Virus Reactivation in HBsAg−/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis2020 · 56 citations
  4. 4Safety of long‐term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection2015 · 100 citations
  5. 5Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti–hepatitis B core antigen positive) with rheumatic diseases2010 · 125 citations